France considering stake in Sanofi's Opella, minister says
PARIS, Oct 15 (Reuters) -France is considering taking a stake in Sanofi's SASY.PA Opella arm, said finance minister Antoine Armand, to allay concerns that the French drugmaker's plans to sell a 50% stake in Opella to a U.S. private equity firm could result in job cuts.
Trade unions and opposition politicians have expressed unease over Sanofi's decision to sell a controlling 50% stake in Opella - whose brands include painkiller Doliprane - to U.S. private equity firm Clayton Dubilier & Rice.
They fear job cuts and say the sale could impact France's economic sovereignty.
Antoine Armand told the French parliament on Tuesday that the government was looking at all options regarding Opella, including the state being on Opella's board of directors.
"I will tell you quite clearly, nothing is off the table, nothing is excluded," he said.
"I am in the process of examining the French state having a possible presence on the board of directors, as well as taking a stake in the company, because the sovereign, industrial strategy we have built up over the past few years is not something to be bargained over," he added.
Armand had also said earlier this week that the French government wanted guarantees from Sanofi that production of Doliprane would stay in France.
Reporting by Bertrand Boucey and Sudip Kar-Gupta;
Editing by Benoit Van Overstraeten
免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。
所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。
本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。
